Plain-language summary

This Phase 2 trial is evaluating Aclarubicin, Cyclophosphamide, and other medications as a treatment for people newly diagnosed with a type of T-cell lymphoma called AITL. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 65 Years or older
• Newly diagnosed, not yet treated
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Aclarubicin (DRUG): 20mg/m\^2/D, D1-4, QD, ivgtt | Cyclophosphamide (DRUG): 750 mg/m\^2, D1, ivgtt | Vincristine (DRUG): 1.4 mg/m\^2, D1 (maximum 2mg/d), IV | Prednisone (DRUG): 60 mg/m\^2, D1-5 (maximum 100mg/d), Po

Drugs / treatments

Aclarubicin, Cyclophosphamide, Vincristine, Prednisone

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details